Ontology highlight
ABSTRACT:
SUBMITTER: Lefebvre E
PROVIDER: S-EPMC5351328 | biostudies-literature | 2016 Jun
REPOSITORIES: biostudies-literature
Lefebvre E E Gottwald M M Lasseter K K Chang W W Willett M M Smith P F PF Somasunderam A A Utay N S NS
Clinical and translational science 20160512 3
Cenicriviroc, a dual CCR2/CCR5 antagonist, is being evaluated for treatment of nonalcoholic steatohepatitis and liver fibrosis (CENTAUR; NCT02217475). As it is metabolized by the liver, cenicriviroc was investigated in hepatic-impaired participants for pharmacokinetic changes. Participants with mild-to-moderate hepatic impairment (HI) (Child-Pugh class A (N = 7) or B (N = 8)) and matched controls (N = 15) received cenicriviroc 150 mg once daily for 14 days. Serial blood samples were obtained o ...[more]